Cyclin-dependent Kinase Inhibitor 1B Expression Research Articles

Low CDKN1B Expression Associated with Reduced CD8+ T Lymphocytes Predicts Poor Outcome in Breast Cancer in a Machine Learning Analysis.

The cyclin-dependent kinase inhibitor 1B (CDKN1B) gene, which encodes the p27Kip1 protein, is important in regulating the cell cycle process and cell proliferation. Its role in breast cancer prognosis is controversial. We evaluated the significance and predictive role of CDKN1B expression in breast cancer prognosis. We investigated the clinicopathologic factors, survival rates, immune cells, gene sets, and prognostic models according to CDKN1B expression in 3794 breast cancer patients. We performed gene set enrichment analysis (GSEA), in silico cytometry, pathway network analyses, gradient boosting machine (GBM) learning, and in vitro drug screening. High CDKN1B expression levels in breast cancer correlated with high lymphocyte infiltration signature scores and increased CD8+ T cells, both of which were associated with improved prognosis in breast cancer. which were associated with a better prognosis. CDKN1B expression was associated with gene sets for the upregulation of T-cell receptor signaling pathways and downregulation of CD8+ T cells. Pathway network analysis revealed a direct link between CDKN1B and the pathway involved in the positive regulation of the protein catabolic process pathway. In addition, an indirect link was identified between CDKN1B and the T-cell receptor signaling pathway. In in vitro drug screening, BMS-345541 demonstrated efficacy as a therapeutic targeting of CDKN1B, effectively impeding the growth of breast cancer cells characterized by low CDKN1B expression. The inclusion of CDKN1B expression in GBM models increased the accuracy of survival predictions. CDKN1B expression plays a significant role in breast cancer progression, implying that targeting CDKN1B might be a promising strategy for treating breast cancer.

CircUBAP2 ameliorates hypoxia-induced acute myocardial injury by competing with miR-148b-3p and mediating CDKN1B expression

BackgroundA recent high-throughput sequencing study revealed an anomalous underexpression of circular RNA UBAP2 (circUBAP2) in acute myocardial infarction (AMI), yet its biological function within this context remains elusive. This study aims to unravel whether circUBAP2 is instrumental in modulating the pathogenesis of AMI and to illuminate the underlying molecular mechanisms at play. ResultscircUBAP2 was abnormally low expressed in AMI. Inducing circUBAP2 ameliorated hypoxia-induced myocardial cell injury by enhancing cellular viability, and decreasing lactate dehydrogenase release, apoptosis, inflammation, and oxidative damage. circUBAP2 targeted miR-148b-3p, miR-148b-3p overexpression offset circUBAP2-induced cardioprotection. Cyclin-dependent kinase inhibitor 1B (CDKN1B) was mediated by miR-148b-3p, and CDKN1B upregulation suppressed the deleterious effect of circUBAP2 silencing on hypoxic AC16 cells. In addition, overexpression of circUBAP2 improved myocardial injury, decreased myocardial cell apoptosis, and alleviated inflammation and oxidative stress in AMI mice. ConclusionscircUBAP2 ameliorates AMI by competitively binding to miR-148b-3p and mediating CDKN1B expression.How to cite: Li F, Xu L, Ou J, et al. circUBAP2 ameliorates hypoxia-induced acute myocardial injury by competing with miR-148b-3p and mediating CDKN1B expression. Electron J Biotechnol 2024;68. https://doi.org/10.1016/j.ejbt.2023.11.003.

GAS5 Suppresses Cell Proliferation, Migration, and Invasion via the miR-455-5p/CDKN1B Axis in Cutaneous Squamous Cell Carcinoma.

Cutaneous squamous cell carcinoma (cSCC) is a common dermatologic malignancy characterized by aberrant proliferation of keratinocytes. Molecular targeted therapy appears to be a promising approach for advanced cSCC. Long noncoding RNA growth arrest specific 5 (GAS5) was reported to be downregulated in skin cancer tissues. This study aimed to explore the functions and underlying mechanism of GAS5 in the development of cSCC. GAS5 expression in cSCC cells was examined by reverse transcription quantitative polymerase chain reaction. The localization of GAS5 in cSCC cells was detected by subcellular fractionation assays. The viability, proliferation, apoptosis, migration, and invasion of cSCC cells after indicated transfection were examined by Cell Counting Kit-8 assays, colony formation assays, TdT-mediated dUTP Nick-End Labeling assays, wound healing assays, and Transwell assays. Western blot analysis was performed to quantify the protein level of messenger RNA cyclin-dependent kinase inhibitor 1B (CDKN1B). In addition, luciferase reporter assays, RNA pulldown assays and RNA immunoprecipitation assays were carried out to explore the binding relation between miR-455-5p and GAS5 (or CDKN1B). GAS5 was lowly expressed in cSCC cells and was primarily located in cytoplasm. GAS5 overexpression inhibited cell viability, proliferation, migration, and invasion while enhancing cell apoptosis. In addition, GAS5 interacted with miR-455-5p to positively regulate CDKN1B expression. CDKN1B is a direct target of miR-455-5p. Furthermore, CDKN1B knockdown rescued the suppressive effect of GAS5 overexpression on malignant behaviors of cSCC cells. GAS5 suppresses cSCC cell proliferation, migration, and invasion by targeting the miR-455-5p/CDKN1B axis. This study provides novel insight into the role of GAS5 in cSCC development.

Regulation of GDF9 and CDKN1B expression in Tibetan sheep testes during different stages of maturity

Normal spermatogenesis is heavily dependent on the balance of germ cell proliferation, differentiation and apoptosis. Growth differentiation factor 9 (GDF9) and cyclin-dependent kinase inhibitor 1 B (CDKN1B) are strongly associated with cell cycle transition from G0/G1 to S and G2/M phase and hence regulating the growth and development of testicular germ cells and somatic cells. The current study was aimed at seeking out scientific evidence to determine if GDF9 and CDKN1B gene expression functions in the development of Tibetan sheep testes. To this end, developmental testes were derived from three-month-old (pre-puberty), one-year-old (sexual maturity), and three-year-old (adult) Tibetan sheep and then the expression and localization patterns of GDF9 and CDKN1B in these testes were evaluated using quantitative real-time PCR (qRT-PCR), Western blot and immunofluorescence. qRT-PCR and Western blot results showed that GDF9 and CDKN1B were detected in the testes throughout the different developmental stages. The abundance of GDF9 mRNA and protein in the testes of one- and three-year-old Tibetan sheep were higher than that in the testes of three-month-old Tibetan sheep; the mRNA and protein abundance of the CDKN1B gene in three-month-old Tibetan sheep testes were higher than that in the testes of the one-and three-year-old sheep. Moreover, immunofluorescence results suggested that the GDF9 protein was expressed in spermatogonia and Leydig cells, and that the CDKN1B protein was localized mainly in Leydig cells with some in the seminiferous epithelium throughout developmental stages. This indicated a novel role of the GDF9 and CDKN1B genes in Leydig cell development over and above their known roles in germ cell development. These findings have significant implications for our understanding of the molecular mechanisms of GDF9 and CDKN1B genes in Tibetan sheep spermatogenesis.

MiR-579-3p Protects Intestinal Mucosal Epithelial Cells from Hypoxia-Reoxygenation Injury by Targeting Cyclin-Dependent Kinase Inhibitor 1B

Intestinal ischemia/reperfusion (I/R) injury is a common tissue and organ injury during surgery. This study explores miR-579-3p’s effect on the hypoxia-reoxygenation injury of intestinal mucosal epithelial cells via cyclin-dependent kinase inhibitor 1B (CDKN1B). Fetal human cells (FHC) cells, which are human normal colorectal mucosal epithelial cells, were cultured in vitro to establish a hypoxia-reoxygenation (H/R) cell model. Nano-based qRT-PCR and Western blot detected miR-579-3p and CDKN1B expressions in HCCLM3 cells treated with H/R. CCK-8 method and flow cytometry measured miR-579-3p and CDKN1B expressions on cell activity and death after H/R treatment. Dual-Luciferase reporter experiment and Western blot analyzed the relationship between miR-579-3p and CDKN1B. After the FHC cells were treated with H/R, miR-579-3p expression was decreased, whereas CDKN1B expression was increased (P < 0.05). FHC cells’ activity was decreased, and its apoptosis rate was upregulated; also, TNF-α and IL-6 protein levels were significantly enhanced (P < 0.05). Nevertheless, the activity of FHC cells treated with H/R after miR-579-3p overexpression was significantly increased, while the apoptosis rate was upregulation, and TNF-α level, IL-6 levels were reduced (P < 0.05). The effect of inhibiting CDKN1B expression was the same as that of overexpression miR-579-3p. After CDKN1B overexpression, the H/R-treated FHC cells’ viability was reduced, while the apoptosis rate was elevated, and TNF-α and IL-6 levels were elevated (P < 0.05). Compared to miR-579-3p overexpression, FHC cell activity in treated with H/R after the overexpression of miR-579-3p+CDKN1B was reduced. At the same time, the apoptosis rate and the level of TNF-α and IL-6 protein were elevated (P < 0.05). In summary, MiR-579-3p’s targeting of CDKN1B protects FHC cells from H/R injury by alleviating H/R-induced apoptosis and inflammation.

Targeting of CDKN1B by miR-222-3p may contribute to the development of intervertebral disc degeneration.

MicroRNAs (miRNAs) are small endogenous non‐coding RNAs that can negatively regulate the expression of their complementary mRNA targets, and have been implicated in various pathophysiological processes. In this study, we examined the effect of miR‐222‐3p on intervertebral disc degeneration (IDD). We found that expression of miR‐222‐3p was significantly higher in IDD tissues than in normal intervertebral disc tissue, and report that overexpression of miR‐222‐3p remarkably increased apoptosis and reduced proliferation of nucleus pulposus (NP) cells. In addition, miR‐222‐3p promoted secretion of matrix metalloproteinase‐3, and decreased collagen type II and aggrecan production. Cyclin‐dependent kinase inhibitor 1B (CDKN1B) was identified as a direct target of negative regulation by miR‐222‐3p in NP cells, and expression of miR‐222‐3p was found to be negatively correlated with that of CDKN1B in IDD tissue. Finally, we observed that transfection with miR‐222‐3p dramatically reduced CDKN1B expression in NP cells. In conclusion, miR‐222‐3p may be involved in IDD development, possibly through targeting CDKN1B.

MiR-155-5p promotes fibroblast cell proliferation and inhibits FOXO signaling pathway in vulvar lichen sclerosis by targeting FOXO3 and CDKN1B

Vulvar lichen sclerosis (VLS) is a chronic inflammatory skin disorder. Evidence is accumulating that microRNAs (miRNAs) exert crucial roles in initiation and development of a wide range of human diseases. MiR-155-5p has been frequently reported to be implicated in the tumorigenesis and progression of multiple types of cancers, however, its biological role in VLS remains unclear. This study aimed to explore the role of miR-155-5p in VLS and clarify the potential molecular mechanisms involved. In the present study, miR-155-5p was observed to be significantly upregulated in VLS tissues. Functional studies showed that miR-155-5p facilitated cell proliferation, accelerated cell cycle progression and inhibited forkhead box O (FOXO) signaling pathway in fibroblast cells. Mechanical studies demonstrated that miR-155-5p exerted its promoting effects on fibroblast cell proliferation via targeting both forkhead box O3 (FOXO3) and cyclin-dependent kinase inhibitor 1B (CDKN1B). Besides, Pearson's correlation analysis revealed that miR-155-5p expression was negatively correlated with the mRNA expression of FOXO3 and CDKN1B in VLS tissues. Taken together, our results indicate that miR-155-5p promotes fibroblast cell proliferation and inhibits FOXO signaling pathway by negative modulation of both FOXO3 and CDKN1B in VLS, and that miR-155-5p may be used to be a potential therapeutic target for VLS.

The Role of Skp2 and its Substrate CDKN1B (p27) in Colorectal Cancer

Colorectal cancer is one of the most frequent cancers worldwide, having the fourth mortality rate among cancers in both sexes. Numerous studies are investigating the signalling pathways and different factors involved in the development and progression of colorectal cancer. It has recently been shown that the S-phase kinase-associated protein 2 (Skp2) overexpression plays an important role in the pathogenesis of colorectal cancer. We review the role of Skp2 and its ubiquitin-proteasome pathway in colorectal cancer. The F-box protein Skp2, a component of the SCF (Skp1-Cullin 1-F-box) E3 ubiquitin-ligase complex, has been shown to regulate cellular proliferation, cancer progression and metastasis by targeting several cell cycle regulators for ubiquitination and subsequent 26S proteasome degradation. The best known protein substrate of the Skp2 is the cyclin-dependent kinase inhibitor 1B (CDKN1B), also known as p27Kip1. Overexpression of Skp2 and loss of CDKN1B (p27) was strongly associated with aggressive tumor behavior and poor clinical outcome in a variety of cancers, including colorectal cancer. An efficient interaction between Skp2 and CDKN1B (p27) requires the presence of an essential activator of the SCF-Skp2 complex, the cyclin-dependent kinase subunit 1 (Cks1) cofactor. Alterations in the Skp2, Cks1 and CDKN1B (p27) expression have major effects on colorectal carcinogenesis and may serve as an important and independent prognostic marker. Furthermore, we highlight that Skp2 may be a promising therapeutic target for colorectal cancer, and development of Skp2 inhibitors would have a great impact on colorectal cancer therapy.

MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B

Dysregulation of miR-452 has been observed in many tumors, but its biological function in hepatocellular carcinoma (HCC) is still unknown. Our results showed that miR-452 expression is significantly increased in HCC tissues and HCC cell lines. We also found that overexpression of miR-452 dramatically accelerated proliferation, induced cell cycle from G1 to S transition, and blocked apoptosis of HCC cells. Migration and matrigel invasion assays indicated that miR-452 significantly promotes HepG2 and QGY-7703 cells migration and invasion in vitro. Further studies showed that miR-452 directly targets the 3'-untranslated region of cyclin-dependent kinase inhibitor 1B (CDKN1B), ectopic miR-452 expression suppressed CDKN1B expression on mRNA and protein level. Silencing CDKN1B by small interfering RNA resembled the phenotype resulting from ectopic miR-452 expression. This study provides new insights into the potential molecular mechanisms that miRNA-452 contributed to HCC.

Overexpression of CDKN1B Inhibits Fibroblast Proliferation in a Rabbit Model of Experimental Glaucoma Filtration Surgery

To investigate the potential antiproliferative effect of cyclin-dependent kinase inhibitor 1B (CDKN1B) overexpression in a rabbit model of glaucoma filtration surgery (GFS). The recombinant adenovector expressing exogenous CDKN1B was delivered to Tenon's capsule by subconjunctival injection during unilateral filtration surgery. The time course of CDKN1B expression was monitored by immunohistochemistry and Western blot analysis. Evaluation of proliferating activity was performed by proliferating cell nuclear antigen (PCNA), argyrophilic nucleolar organizing region (AgNOR) staining, and fibroblast-specific protein 1 (FSP-1). Cyclin-dependent kinase 2 (Cdk2) and Cdk4 expression were detected with immunohistochemical analysis. The overexpression of CDKN1B in Tenon's capsule was monitored throughout the experimental period. Immunoreactivity to CDKN1B was mainly observed in the nucleus of fibroblasts. The increased expression of CDKN1B in sclera was detected up to 21 days after viral infection, whereas the level of CDKN1B protein in corneal stroma was not significantly increased. The overexpression of CDKN1B induced a significant decrease in AgNOR number/nucleus and area/nucleus, PCNA staining, FSP-1 positive cells, and the decreased expressions of Cdk2 and Cdk4, as evidenced by nuclear and cytoplasmic immunoreactivity to Cdk2 and Cdk4 antibodies in positive fibroblasts. The persistent overexpression of CDKN1B mediated by the recombinant adenovector expressing exogenous CDKN1B in Tenon's fibroblasts after GFS may lead to the inhibition of fibroblast proliferation and the downregulation of Cdk2 and Cdk4 activity, thereby reducing the severity of scar formation and the surgical outcome.